Ovarian cancer continues to be the main cause of death among all gynecological tumors. After standard treatments, most of patients are destined to recur within a short period, thus new therapies are urgently needed. The increasing knowledge of molecular mechanisms in ovarian cancer pathogenesis allowed identifying several targeted agents that are now entering in clinical practice. The family of poly(ADP-ribose) polymerase inhibitors represents a widely investigated and promising alternative for the targeted therapy of ovarian malignancies. PARP inhibitors exploit the synthetic lethality concept to prevent the repair of DNA damage, causing cancer cell death. This review describes the molecular mechanisms at the basis of PARP inhibition, particularly in BRCA-related ovarian malignancies and analyzes the main agents under investigations in preclinical and clinical studies. © 2013 Toss A, et al.

Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer / Toss, A.; Laura, C.. - In: JOURNAL OF CANCER SCIENCE & THERAPY. - ISSN 1948-5956. - 5:11(2013), pp. 409-416. [10.4172/1948-5956.1000234]

Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer

Toss A.;
2013

Abstract

Ovarian cancer continues to be the main cause of death among all gynecological tumors. After standard treatments, most of patients are destined to recur within a short period, thus new therapies are urgently needed. The increasing knowledge of molecular mechanisms in ovarian cancer pathogenesis allowed identifying several targeted agents that are now entering in clinical practice. The family of poly(ADP-ribose) polymerase inhibitors represents a widely investigated and promising alternative for the targeted therapy of ovarian malignancies. PARP inhibitors exploit the synthetic lethality concept to prevent the repair of DNA damage, causing cancer cell death. This review describes the molecular mechanisms at the basis of PARP inhibition, particularly in BRCA-related ovarian malignancies and analyzes the main agents under investigations in preclinical and clinical studies. © 2013 Toss A, et al.
2013
5
11
409
416
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer / Toss, A.; Laura, C.. - In: JOURNAL OF CANCER SCIENCE & THERAPY. - ISSN 1948-5956. - 5:11(2013), pp. 409-416. [10.4172/1948-5956.1000234]
Toss, A.; Laura, C.
File in questo prodotto:
File Dimensione Formato  
molecular-mechanisms-of-parp-inhibitors-in-brcarelated-ovarian-cancer-1948-5956.1000234.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 2.07 MB
Formato Adobe PDF
2.07 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1179843
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 21
  • ???jsp.display-item.citation.isi??? ND
social impact